Intensity Therapeutics’ INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers
- Friday, November 11, 2022, 7:10
- Environment
- Add a comment
Patients Receiving INT230-6 Alone (n=64) had a Median Overall Survival (mOS) of 373 Days Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors Combined with Pembrolizumab in a Population Consisting of Heavily…
About the Author
adminasapcorp has written 41806 stories on this site.